PhytoHealth Corporation announced the company's current R&D progress on anti-osteoporosis. Cause of occurrence 1) In accordance with the provisions on financial statements disclosure, the company makes a public announcement on the R&D progress of the one new drugs currently in development. 2) Concerning new drug R&D stages and workflow from bench to marke. As requested by Taiwan Stock Exchange Corporation's letter No.1051801037 issued on Mar.11,2016. a) New drug in development 1: Anti-osteoporosis Clinical trial for preventing osteoporosis: (a) Trial Title: PH3 for the Prevention of Osteoporosis in Post-menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study. (b) Institution: TVGH, CGMH, NTUH and MMH. (c) Trial Update: Phase II clinical study was completed. The company continues to assess the compatibility of clinical trial regulations between Taiwan and China and to explore clinical trial cooperation possbility in accordance with clinical trials harmonization. (d) Filed IND annual report to US-FDA on May 3, 2021. e) The manufacturing process of PH3 is continuously being optimized to fulfill the CMC requirement for larger scale production of PH3. The specifications of PH3 drug product would be maintained to ensure batch to batch consistency and product quality. (f) Continuous monitoring of species identification and cultivation.